Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sangamo Shoots Up As Regulatory Path Clears For Fabry Gene Therapy

Feb 13 2024

• By Kevin Grogan

Lab — • Source: Sangamo

Related Content

Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse

Mar 21 2023

Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen

Jul 18 2023

Sangamo's Fabry Gene Therapy May Be A STAAR In The Making

Nov 05 2021

Related Companies

Sangamo Therapeutics, Inc.

Novartis AG

Biogen, Inc.

Prevail Therapeutics Inc.

Eli Lilly and Company

Additional Topics

Gene Therapy Clinical Trials FDA Business Strategies Regulation Regulatory Research & Development BioPharmaceutical

More from Gene Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window